Collegium Pharmaceutical
Abuse-deterrent Pharmaceutical Products for Chronic Pain.
HQ location
Cumberland, United States
Website
Launch date
Employees
Market cap
$962m
Enterprise value
$1.6b
Share price
$29.57 COLL
Recent deals
loading funding rounds…
Eventide Asset Management(exited)
Frazier Healthcare Partners(exited)
TPG Biotech(exited)
RA Capital Management(exited)
Boston Millennia Partners(exited)
EcoR1 Capital(exited)
Longitude Capital(exited)
Skyline Ventures(exited)
Aperture Venture Partners(exited)
Rock Springs Capital(exited)
Westfield Capital Management(exited)
Aperture Ventures Partners(exited)
TPG(exited)
National Institute on Drug Abuse(exited)
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (11 %) | 68 % | 22 % | 11 % | 18 % | 4 % | (7 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 8 % | 7 % | 59 % | 55 % | 59 % | 56 % | 52 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 26 % | (5 %) | 8 % | 11 % | 6 % | 7 % | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 3 % | 1 % | - | - | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Collegium Pharmaceutical
Edit
ACQUISITION by Collegium Pharmaceutical Feb 2022
ACQUISITION by Collegium Pharmaceutical Jul 2024